American Journal of Epidemiology Vol. 128, No. 3: 606-614
Copyright © 1988 by The Johns Hopkins University School of Hygiene and Public Health
research-article |
POSTMENOPAUSAL ESTROGEN USE AND MORTALITY
RESULTS FROM A PROSPECTIVE STUDY IN A DEFINED, HOMOGENEOUS COMMUNITY
1Department of Community and Family Medicine, University of California at San Diego La Jolla, CA 92093
2Bureau of Epidemiology, Texas Department of Health Austin, TX
Reprint requests to Dr. Michael H. Criqui
The authors studied the association between postmenopausal estrogen use and mortality from cardiovascular disease, coronary heart disease, cancer, and all causes in a cohort of 1,868 women aged 50–79 years residing in a planned community. After 12 years, the age-adjusted all-cause mortality rate was lower in the 734 postmenopausal estrogen users (14.9/100 women) compared with the 1,134 nonusers (21.5/100 women) (relative risk (RR)=0.69, 95% confidence interval (CI) 0.55–0.87). After adjustment for age, systolic blood pressure, social class, fasting plasma cholesterol, fasting plasma glucose, Quetelet index (weight (lbs)/height (in)2x100), and cigarette smoking by the Cox model, the relative risk increased to 0.79 (95% CI 0.62–1.01). Because a postmenopausal estrogen-smoking interaction term was significant (p=0.025), separate Cox models were run for never, past, and current smokers. In never and current smokers, estrogen was protective for all-cause mortality, with relative risks of 0.67 (95% CI 0.45–0.99) and 0.62 (95% Ci 0.39–0.98), respectively. However, past smokers were not protected by postmenopausal estrogen use (AR=1.32, 95% CI 0.84–2.08). Cause-specific models revealed differences in the association of postmenopausal estrogen use with cardiovascular disease mortality and coronary heart disease mortality that were dependent on smoking status. Postmenopausal estrogen use was strongly protective in current smokers but was associated with increased risk in past smokers. As expected, cancer mortality was increased in smokers. The confidence intervals for the relative risk estimate of postmenopausal estrogen use for cancer mortality in each smoking category included one. Finally, a separate analysis of subsequent three-year mortality in women surviving the first nine years of follow-up revealed reduced death rates only for women using estrogen at both baseline and nine years of follow-up, suggesting both a conservative bias in our data introduced by the large reduction in postmenopausal estrogen use during the study period and the possibility of a stronger protective effect for recent postmenopausal estrogen use.
cancer; cardiovascular diseases; coronary heart disease; estrogens; meno pause; mortality; smoking
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. A. Tice, A. Kanaya, T. Hue, S. Rubin, D. S. M. Buist, A. LaCroix, J. V. Lacey Jr, J. A. Cauley, S. Litwack, L. A. Brinton, et al. Risk Factors for Mortality in Middle-aged Women Arch Intern Med, December 11, 2006; 166(22): 2469 - 2477. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Jayachandran and V. M. Miller Mechanisms of estrogenic vascular protection Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H507 - H508. [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Prentice, R. Langer, M. L. Stefanick, B. V. Howard, M. Pettinger, G. Anderson, D. Barad, J. D. Curb, J. Kotchen, L. Kuller, et al. Combined Postmenopausal Hormone Therapy and Cardiovascular Disease: Toward Resolving the Discrepancy between Observational Studies and the Women's Health Initiative Clinical Trial Am. J. Epidemiol., September 1, 2005; 162(5): 404 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. M. Miller, T. B. Clarkson, S. M. Harman, E. A. Brinton, M. Cedars, R. Lobo, J. E. Manson, G. R. Merriam, F. Naftolin, and N. Santoro Women, hormones, and clinical trials: a beginning, not an end J Appl Physiol, August 1, 2005; 99(2): 381 - 383. [Full Text] [PDF]
|
|
|
|
 |
|
 M. J Stampfer and G. A Colditz Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence Int. J. Epidemiol., June 1, 2004; 33(3): 445 - 453. [Full Text] [PDF]
|
|
|
|
 |
|
 Canadian Task Force on Preventive Health Care Postmenopausal hormone replacement therapy for primary prevention of cardiovascular and cerebrovascular disease: Recommendation statement from the Canadian Task Force on Preventive Health Care Can. Med. Assoc. J., April 27, 2004; 170(9): 1388 - 1389. [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Humphrey, H. D. Nelson, B. K. S. Chan, P. Nygren, J. Allan, and S. Teutsch Relationship Between Hormone Replacement Therapy, Socioeconomic Status, and Coronary Heart Disease JAMA, January 1, 2003; 289(1): 45 - 45. [Full Text] [PDF]
|
|
|
|
|
|
H. D. Nelson, L. L. Humphrey, P. Nygren, S. M. Teutsch, and J. D. Allan Postmenopausal Hormone Replacement Therapy: Scientific Review JAMA, August 21, 2002; 288(7): 872 - 881. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Humphrey, B. K.S. Chan, and H. C. Sox Postmenopausal Hormone Replacement Therapy and the Primary Prevention of Cardiovascular Disease Ann Intern Med, August 20, 2002; 137(4): 273 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Hedblad, J. Merlo, J. Manjer, G. Engstrom, G. Berglund, and L. Janzon Incidence of cardiovascular disease, cancer and death in postmenopausal women affirming use of hormone replacement therapy Scand J Public Health, January 1, 2002; 30(1): 12 - 19. [Abstract] [PDF]
|
|
|
|
|
|
C. Rodriguez, E. E. Calle, A. V. Patel, L. M. Tatham, E. J. Jacobs, and M. J. Thun Effect of Body Mass on the Association between Estrogen Replacement Therapy and Mortality among Elderly US Women Am. J. Epidemiol., January 15, 2001; 153(2): 145 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Mosca The Role of Hormone Replacement Therapy in the Prevention of Postmenopausal Heart Disease Arch Intern Med, August 14, 2000; 160(15): 2263 - 2272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Perry III The Endocrinology of Aging Clin. Chem., August 1, 1999; 45(8): 1369 - 1376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Prescott, M. Hippe, P. Schnohr, H. O. Hein, and J. Vestbo Smoking and risk of myocardial infarction in women and men: longitudinal population study BMJ, April 4, 1998; 316(7137): 1043 - 1047. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. A. Bellinger, J. K. Williams, M. R. Adams, E. K. Honore, and D. E. Bender Oral Contraceptives and Hormone Replacement Therapy Do Not Increase the Incidence of Arterial Thrombosis in a Nonhuman Primate Model Arterioscler Thromb Vasc Biol, January 1, 1998; 18(1): 92 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Cauley, D. G. Seeley, W. S. Browner, K. Ensrud, L. H. Kuller, R. C. Lipschutz, and S. B. Hulley Estrogen Replacement Therapy and Mortality Among Older Women: The Study of Osteoporotic Fractures Arch Intern Med, October 27, 1997; 157(19): 2181 - 2187. [Abstract] [PDF]
|
|
|
|
|
|
S. E. McNagny and T. A. Jacobson Use of Postmenopausal Hormone Replacement Therapy by African American Women: The Importance of Physician Discussion Arch Intern Med, June 23, 1997; 157(12): 1337 - 1342. [Abstract] [PDF]
|
|
|
|
 |
|
 F. Grodstein, M. J. Stampfer, G. A. Colditz, W. C. Willett, J. E. Manson, M. Joffe, B. Rosner, C. Fuchs, S. E. Hankinson, D. J. Hunter, et al. Postmenopausal Hormone Therapy and Mortality N. Engl. J. Med., June 19, 1997; 336(25): 1769 - 1776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Zumoff The Critical Role of Alcohol Consumption in Determining the Risk of Breast Cancer with Postmenopausal Estrogen Administration J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1656 - 1658. [Full Text] [PDF]
|
|
|
|
|
|
M. A. Cobleigh, R. F. Berris, T. Bush, N. E. Davidson, N. J. Robert, J. A. Sparano, D. C. Tormey, W. C. Wood, Breast Cancer Committees of the Eastern Cooperativ, R. F. Berris, et al. Estrogen Replacement Therapy in Breast Cancer Survivors: A Time for Change JAMA, August 17, 1994; 272(7): 540 - 545. [Abstract] [PDF]
|
|
|
|
|
|
W F M Potshuma, R G J Westendorp, and J P Vandenbroucke Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased? BMJ, May 14, 1994; 308(6939): 1268 - 1269. [Abstract] [Full Text]
|
|
|
|
|
|
P. E. Belchetz Hormonal Treatment of Postmenopausal Women N. Engl. J. Med., April 14, 1994; 330(15): 1062 - 1071. [Full Text]
|
|
|
|
|
|
F. E. Kuhn and C. E. Rackley Coronary Artery Disease in Women: Risk Factors, Evaluation, Treatment, and Prevention Arch Intern Med, December 13, 1993; 153(23): 2626 - 2636. [Abstract] [PDF]
|
|
|
|
|
|
M. R. Soma, I. Osnago-Gadda, R. Paoletti, R. Fumagalli, J. D. Morrisett, M. Meschia, and P. Crosignani The Lowering of Lipoprotein[a] Induced by Estrogen Plus Progesterone Replacement Therapy in Postmenopausal Women Arch Intern Med, June 28, 1993; 153(12): 1462 - 1468. [Abstract] [PDF]
|
|
|
|
|
|
F. F. Finucane, J. H. Madans, T. L. Bush, P. H. Wolf, and J. C. Kleinman Decreased Risk of Stroke Among Postmenopausal Hormone Users: Results From a National Cohort Arch Intern Med, January 11, 1993; 153(1): 73 - 79. [Abstract] [PDF]
|
|
|
|
|
|
D. Grady, S. M. Rubin, D. B. Petitti, C. S. Fox, D. Black, B. Ettinger, V. L. Ernster, and S. R. Cummings Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women Ann Intern Med, December 15, 1992; 117(12): 1016 - 1037. [Abstract] [PDF]
|
|
|
|
|
|
B. E. Henderson, A. Paganini-Hill, and R. K. Ross Decreased Mortality in Users of Estrogen Replacement Therapy Arch Intern Med, January 1, 1991; 151(1): 75 - 78. [Abstract] [PDF]
|
|
|
|
|
|
E. Barrett-Connor, D. L. Wingard, and M. H. Criqui Postmenopausal Estrogen Use and Heart Disease Risk Factors in the 1980s: Rancho Bernardo, Calif, Revisited JAMA, April 14, 1989; 261(14): 2095 - 2100. [Abstract] [PDF]
|
|